Summary The receptor-type oncogenes c-erbB2/neu and c-erbB have been found amplified and/or overexpressed in a number of tumours of epithelial origin. We have studied the expression of oncogenes in biopsies from human thyroid tumours. The c-erbB2/neu and c-erbB oncogenes showed two-to three-fold higher levels of RNA in papillary carcinomas and lymph node metastases as well as in one adenoma when compared to non-tumour tissue. The nuclear oncogenes c-myc and c-fos were found to be expressed at varying levels in both non-tumour and tumour tissue. RNA transcripts specific for the platelet-derived growth factor A and B chains and the N-ras oncogene were detected in one anaplastic carcinoma. Neither rearrangements nor amplifications of oncogenes were observed in the thyroid tumours. These data are particularly interesting in light of the recent findings that epidermal growth factor induces proliferation and dedifferentiation of normal thyroid epithelial cells in vitro. We suggest that the epidermal growth factor or other ligands for the c-erbB and c-erbB2/neu receptors may contribute to the development and/or maintenance of the malignant phentotype of papillary carcinomas of the thyroid.
Strong evidence has accumulated supporting the hypothesis that abnormalities in either the structure or activity of proto-oncogenes contribute to the development and/or maintenance of the malignant phenotype. The expression of oncogenes has been investigated in several types of human malignancies, most extensively by Slamon et al. (1984) . In some cases tumour aggressivity and state of differentiation have been correlated to the expression of certain oncogenes. The N-myc oncogene has been found abundantly expressed in poorly differentiated regions of neuroblastomas (Schwab, 1985) .
The c-erbB oncogene encodes the receptor for epidermal growth factor (EGF) (Downward et al., 1984) and transforming growth factor alpha (TGF-a) (Todaro et al., 1980) . The more recently discovered c-erbB2/neu oncogene is distinct from, but closely related to c-erbB and encodes a receptor-like glycoprotein with tyrosine kinase activity for which a ligand has not yet been identified (Bargmann et al., 1986; Akiyama et al., 1986; Yamamoto et al., 1986a) .
The c-erbB oncogene has been found overexpressed and/or amplified in a number of cancers of epithelial origin such as squamous carcinomas (Yamamoto et al., 1986a,b) and in brain tumours (Libermann et al., 1985) . Elevated expression of the c-erbB2/neu gene has been reported to accompany the amplification in several instances (King et al., 1985; Fukushige et al., 1986; Yokota et al., 1986; Kraus et al., 1987) . Recently, the c-erbB2/neu oncogene was found amplified in a large number of mammary carcinomas, and a strong correlation between c-erbB2/neu-amplification and poor prognosis of the disease was observed (Slamon et al., 1987) . The c-fos and c-myc oncogenes have been found expressed at elevated levels in a wide range of human tumours (Slamon et al., 1984) .
The study of oncogene expression in human tumours may thus become an important tool in the diagnosis and the evaluation of prognosis of specific types of malignant tumours. Thyroid tumours have been largely excluded from the surveys of oncogene expression in human tumours, probably due to the low incidence and low mortality from thyroid cancer. Only recently, evidence was presented for the existence of a new transforming gene in thyroid papillary carcinomas and their lymph node metastases (Fusco et al., 1987 Secondly, thyroid cancer displays non-random geographical distribution. In Norway, it is most frequent in the coastal districts (Glattre et al., 1985) . Furthermore it will be of importance to investigate the possible involvement of oncogenes in the trophic hormone control of the thyroid.
In this paper we report data on the expression of the receptor-type oncogenes c-erbB and c-erbB2/neu, and the nuclear oncogenes c-fos and c-myc, in thyroid tumours. Our data show that c-myc and c-fos are expressed abundantly in several of the tumours as well as in non-tumour tissue. In contrast, the highest levels of c-erbB and c-erbB2/neu RNA expression were found in papillary carcinomas and their lymph node metastases. In the tumours from the patients so far tested, neither gross rearrangements nor amplifications of oncogenes have been detected. Purification of DNA and RNA from biopsies Tissue samples taken from thyroid glands or lymph node metastases immediately after surgical removal from patients were frozen in liquid nitrogen without delay and thereafter stored at -80°C until further processing. DNA and total cellular RNA were simultaneously purified from the biopsies using a modification of the method described by Chirgwin et al. (1978) which was briefly as follows: The frozen tissue was minced briefly (max. 30 sec) at 0°C and immediately transferred to the guanidinium thiocyanate homogenization solution. The sample was homogenized in a Dounce's homogenizer, filtered through cheesecloth, added 1 g CsCl/2.5 ml and layered on top of a 1.25 ml cushion of 5.7 M CsCl in 0.1 M EDTA. Precipitation of RNA and banding of DNA was performed by centrifugation at 20°C for 12 h at 35,000 rpm in a Beckman SW50 rotor. DNA was extracted twice in phenol/chloroform and once in chloroform, ethanolprecipitated, and dissolved in 10mM Tris-HCl/l mM EDTA/pH 7.5. The RNA-pellet was dissolved in 10mM Tris-HCl/l mM EDTA/1 % SDS/pH 7.5, extracted once with chloroform/n-butanol (4:1), ethanol-precipitated, and stored at -20°C until further processing. RNA concentration was determined either spectrophotometrically or by detection of fluorescence at 590 nm in the presence of ethidium bromide (2.5 jgml -1 in PBS; excitation at 360nm).
Materials and methods

Enzymes
Hybridization analysis Restriction enzyme digested DNA was separated by electrophoresis on 0.7% agarose gels and blotted onto nitrocellulose as described by Maniatis et al. (1982) . RNA was slot-blotted onto nitrocellulose as described by Murnane (1986) except that denaturation of RNA was carried out in 12% formaldehyde/105 mM sodiumphosphate/105 mM EDTA/pH 6.5. RNA was separated by electrophoresis in 1 % agarose gels in a MOPS-buffer system in the presence of 2.2 M formaldehyde and blotted onto nitrocellulose. Hybridization to immobilized nucleic acids was performed as described by Maniatis et al. (1982) , in the presence of 50% formamide/5xSSC/200 ugml l heat-denatured salmon sperm DNA/0. 1% SDS/25 mM sodiumphosphate pH 6.5/ 8.25% dextransulphate at 42°C for 15 to 24h. Filters were washed twice for 20 min in 0.2 x SSC/0. 1% SDS at 65°C. When filters were to be rehybridized, the bound probe was first removed by incubation of the filters in 0.1 x SSC for 7min at 95-100°C. Kodak XAR-5 X-ray films were exposed to the nitrocellulose membranes at -80°C in the presence of intensifying screens. Densitometric scanning of the films was carried out using a Zeineh soft laser (Biomed Instruments Inc.) fitted with a HP3390A integrator (Hewlett Packard).
Preparation of hybridization probes DNA fragments were prepared from plasmids and 32P-labelled by nick translation (Rigby et al., 1977) or using the oligo-labelling technique (Feinberg & Vogelstein, 1984) resulting in specific activities ranging from 0.4 to 4x 109cpmpg-1. The probes were purified fragments of cloned human genes. c-fos: 3 kbp XhoI-NcoI fragment of pc-fos-I (Curran et al., 1983) ; c-myc: 1.5 kbp ClaI-EcoRI fragment of pE-H8 (Gazin et al., 1984) ; c-erbB2/neu: 0.44 kbp BamHI fragment of pKXO44 (Semba et al., 1985) and partial cDNA: 1.6 kbp EcoRI fragment of pCER204 (Yamamoto et al., 1986a) ; c-erbB cDNA: 2.4 kbp ClaI fragment of pE7 (Xu et al., 1984) ; N-ras partial cDNA: 0.55 kbp EcoRI-SalI fragment of p6al (Taparowsky et al., 1983) ; PDGF-A cDNA: 1.3 kbp EcoRI fragment of pUC-13-Dl (Betsholz et al., 1986) ; v-sis: 1.2 kbp Pstl fragment of pv-sis (Robbins et al., 1981) ; thyroglobulin partial cDNA: 0.68 and 0.98kbp PstI fragments of phTgl (Brocas et al., 1982) ; Mouse 18S rRNA end-labelled with 32P was a generous gift from Anne M. Oyan, Department of biochemistry, University of Bergen.
Results
Analysis of oncogene expression in thyroid tumours Slot-blot hybridization was the method of choice for detection of oncogene RNA due to its simplicity and high sensitivity. Three sets of slot-blotted RNA samples were prepared. The first set was analyzed by hybridization using probes for c-myc, c-fos, c-erbB2/neu, thyroblobulin, tubulin and 18S ribosomal RNA (Figure 1) . The second set of slotblotted RNA samples were hybridized to probes for c-fos, c-erbB2/neu (Figure 2) , and c-sis, PDGF-A, (Figure 3 ) and L-myc (not shown), and the third set was hybridized to probes for c-myc, c-erbB (Figure 2) , and N-ras (Figure 3) . The results from densitometric scanning of the autoradiograms are presented in Figure 4 .
Expression of c-erbB2/neu and c-erbB All thyroid biopsies contained c-erbB2/neu and c-erbB RNA. Three out of 5 papillary carcinomas (13.4, 15.2 and 17.3) and the 3 lymph node metastases (5.7, 13.5 and 15.3) expressed these oncogenes at 2-to 3-fold higher levels than non-tumour tissue. The highest level of c-erbB2/neu RNA was observed in one of the two adenomas (8.4) while the anaplastic carcinoma (19.1) expressed low levels of both c-erbB2/neu and c-erbB RNA.
The c-erbB2/neu probe used in the first experiment ( Figure  1 ) had a low specific activity (7 x 108 cpm jug-l) and the signals are barely visible; high levels of c-erbB2/neu specific RNA in this experiment were, however, observed in the two metastases (5.7 and 13.5). These results were confirmed in the second hybridization experiment (Figure 2) .
Among the non-thyroid biopsies, the mammary carcinoma (Mc) expressed more than 18-fold higher levels of c-erbB2/ neu RNA than the non-tumour tissues, whereas c-erbB RNA was not detected. This tumour exhibited a more than 20-fold amplification of the c-erbB2/neu gene ( Figure 5 ). The placenta expressed high levels of c-erbB but not c-erbB2/neu. exhibited highest level of c-fos RNA. Notably, several samples of non-tumour tissue contained high levels of c-myc and c-fos RNA. It should also be noted that elevated expression of c-fos was observed in the three papillary carcinomas (13.4, 15.2 and 17.3) expressing the highest levels of c-erbB2/neu and c-erbB specific RNA. The integrity of the RNA was sufficiently maintained as indicated by the presence of the 2.2 and 2.0 kb c-fos transcripts on a Northern blot (Figure 6 ). The low sensitivity in this experiment allowed detection of transcripts only in the four samples from Patients no. 12 and 13. Slight smearing of the fos-transcripts was apparent, indicating that some degradation of RNA had occured. This had most probably taken place during the lengthy and complicated surgical removal of the thyroid. A slight degradation of RNA should not, however, seriously affect the detection of slot blotted RNA.
Expression of other genes N-ras, c-sis and PDGF-A specific RNA was expressed at low but invariant levels in all the thyroid samples (data not shown) except in the anaplastic carcinoma (19.1). This tumour showed 4-fold higher levels of N-ras and PDGF-A RNA as well as traces of c-sis RNA than the other thyroid samples as determined by densitometric scanning of autoradiograms (Figure 3 ). This tumour may therefore produce homo-as well as heterodimers of PDGF. L-myc expression was not detected in any of the samples tested (not shown).
Thyroglobulin specific RNA was expressed at very high levels in all the thyroid samples while being completely absent from the lymphoma and the placenta (Figure 1) . To serve as an internal control, the filter was rehybridized to a tubulin and a mouse 18S rRNA probe (Figure 1) . The results clearly demonstrate that the level of tubulin RNA varied to a great extent among the tissue specimens and thus was of little value as an internal control. The 18S rRNA hybridization indicated that the amount of RNA applied to the filter varied only slightly.
Southern blot-hybridization to tumour DNA In Figure 6 the Southern blot analysis of various thyroid tumour DNAs using the c-erbB2/neu probe is shown. Neither amplification nor rearrangements were found. In contrast, the c-erbB2/neu gene was amplified more than 20-fold in the mammary carcinoma (Mc).
Restriction fragment analyses of the c-myc, c-fos, and cerbB oncogenes as well as others (including c-myb, c-etc-i, csrc, int-i and p53) have also been carried out with DNA from the thyroid tumours. No rearrangements nor amplifications have so far been detected (results not shown).
Discussion
We have studied the expression of oncogenes in fresh biopsies from 8 patients having different types of thyroid tumours and in biopsies from a diffuse toxic goitre and a lyphoma of the thyroid. The expression of the c-erbB and c-erbB2/neu oncogenes was found to be 2-to 3-fold higher in 3 of 5 papillary carcinomas, 3 lymph node metastases, and one adenoma than in non-tumour tissue and the anaplastic carcinoma. Our data extend the list of human tumours in which an elevated expression of the c-erbB2/neu and c-erbB oncogenes is found also to include papillary carcinomas of the thyroid. To decide whether this is a feature of these carcinomas in general, will require further data. The expression of c-erbB2/neu in the thyroid samples was moderate as compared to the mammary carcinoma that contained a >20-fold amplified c-erbB2/neu gene. Intermediate level expression of these receptor type oncogenes may, nevertheless, be important. The A43 1 epidermoid carcinoma cells which are expressing very high levels of EGF-receptors have been found to be inhibited by EGF at concentrations which are mitogenic to other cells (Gill & Lazar, 1981; Barnes, 1982 (Eggo et al., 1984; Roger & Dumont, 1984; Westermark et al., 1983; Waters et al., 1987) . Thus it is possible that an elevated expression of EGF-receptors contributes to the development of a malignant phenotype of thyroid tumours by increasing proliferation and dedifferentiation. Pertinent to this are the reports on the induction by EGF of plasminogen activator which in turn may lead to the degradation of extracellular matrix proteins (Lee & Weinstein, 1978; Stoppelli et al., 1986) . In mammary carcinomas, there is now evidence for the expression of TGF-a and its possible involvement in an autocrine or paracrine stimulation of growth (Dickson et al., 1987 ). An increased level of EGF-receptors may potentiate such stimulation. We are currently investigating whether TGF-oc is expressed in the thyroid tumours. Although EGF did not stimulate the tyrosine kinase activity of the c-erbB2/neu protein, EGF induced tyrosine and serine phosphorylation of the c-erbB2/neu protein (Akiyama et al., 1986; Kadowaki et al., 1987 (Slamon et al., 1984) . Our data add thyroid tumours to this list. The presence of elevated levels of c-myc and c-fos RNA in the non-tumour tissue samples indicates that expression of these genes does not imply malignancy. One should note, however, that the non-tumour biopsies were taken from tumour-bearing thyroids (except the one from a diffuse toxic goitre). It is possible that the entire tumour-bearing thyroids were in a state of growthstimulation that could induce the expression of c-myc and c-fos as has been shown in vitro (Dere et al., 1985; Tramontano et al., 1986; Colletta et al., 1986) . Furthermore, the expression of these genes may be unevenly distributed in the tumours, and we are currently investigating this possibility by means of in situ hybridization.
The anaplastic carcinoma exhibited a markedly different pattern of oncogene expression when compared to the papillary carcinomas. In particular, the c-myc and N-ras oncogenes were expressed at high levels. The anaplastic carcinoma may be an example of a tumour in which the action of these two oncogenes contributes to the transformation in a cooperative manner (Land et al., 1983) . This tumour also expressed RNA specific for the A and B chains of PDGF. These differences may reflect the different properties of these two types of tumours, the anaplastic carcinomas being far more aggressive than the papillary carcinomas.
In a separate line of studies using oligonucleotide Further studies on the expression and regulation of the c-erbB and c-erbB2/neu genes in malignant and nonmalignant thyroid tumours will shed light on the role of these oncogenes in the development and maintenance of a malignant phenotype.
